NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

NextCure, Inc. (NASDAQ:NXTC) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 72,008 shares, a growth of 29.7% from the March 31st total of 55,520 shares. Based on an average trading volume of 63,067 shares, the days-to-cover ratio is currently 1.1 days. Currently, 2.5% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a report on Monday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $23.00.

NextCure Trading Up 6.3%

NASDAQ NXTC traded up $0.58 during trading hours on Friday, reaching $9.79. The company’s stock had a trading volume of 14,830 shares, compared to its average volume of 44,089. The business has a 50-day simple moving average of $11.50 and a 200 day simple moving average of $11.58. NextCure has a 52 week low of $4.09 and a 52 week high of $15.74. The stock has a market cap of $35.35 million, a PE ratio of -0.49 and a beta of 1.57.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, March 5th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($2.26) by $1.45. As a group, equities analysts predict that NextCure will post -8.21 EPS for the current year.

Institutional Investors Weigh In On NextCure

Several large investors have recently added to or reduced their stakes in NXTC. Ikarian Capital LLC acquired a new position in shares of NextCure during the fourth quarter valued at $3,382,000. Squadron Capital Management LLC bought a new stake in NextCure in the 4th quarter valued at about $3,363,000. Millennium Management LLC bought a new stake in NextCure in the 4th quarter valued at about $185,000. Boothbay Fund Management LLC acquired a new position in NextCure during the 4th quarter valued at about $988,000. Finally, Marshall Wace LLP acquired a new position in NextCure during the 4th quarter valued at about $160,000. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.